Small Molecule Drug Discovery Using AstraZeneca's High-Throughput Screening Platform

This funding program supports academic researchers in identifying promising small molecule candidates for drug development using AstraZeneca's extensive resources. Researchers gain access to a library of over two million compounds and cutting-edge high-throughput screening facilities. The Medical Research Council funds up to four projects annually, with each project typically running for 15 months. This is an excellent opportunity for academic institutions seeking to advance early-stage drug discovery research through partnership with a leading pharmaceutical company's proprietary tools and infrastructure.